Unibest
← Back to patent-cliff list

CAS 75-64-9

2-methylpropan-2-amine2-Methylpropan-2-amine1,1-Dimethylethylamine

Codes: RIVA-027, Enalapril-056, Tamsulosin Hydrochloride-101, Carteolol Hydrochloride-009, Rifampicin-023, Timolol Maleate-003

Application context (from source-drug indications)

Pulmonary embolismRivaroxabanStrokeRivaroxabanCongenital heart defectRivaroxabanThrombosisRivaroxabanVenous thromboembolismRivaroxabanCoronary artery diseaseRivaroxabanCardiac and vascular disordersAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHypertensionAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHeart diseaseAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinOcular hypertensionCarteolol Hydrochloride/LatanoprostGlaucomaCarteolol Hydrochloride/LatanoprostOpen-angle glaucomaCarteolol Hydrochloride/LatanoprostLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideEssential hypertensionEnalapril Maleate/Folic AcidMycobacterium tuberculosis infectionEthambutol Hydrochloride/Rifampicin/IsoniazidOcular hypertensionBrimonidine Tartrate/Timolol MaleateGlaucomaBrimonidine Tartrate/Timolol MaleateOcular hypertensionBimatoprost/Timolol MaleateOpen-angle glaucomaBimatoprost/Timolol MaleateGlaucomaBimatoprost/Timolol MaleateBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochlorideHeart failureEnalapril MaleateHypertensionEnalapril MaleateMyocardial infarctionEnalapril MaleateAngina pectorisEnalapril MaleateLeft ventricular dysfunctionEnalapril MaleateSolid tumourEnalapril MaleateOcular hypertensionTimolol MaleateGlaucomaTimolol MaleateOpen-angle glaucomaTimolol MaleateTrauma and injuryTimolol MaleateHypertensionTimolol MaleateMigraineTimolol MaleateHypertensionCarteolol HydrochlorideOcular hypertensionCarteolol HydrochlorideGlaucomaCarteolol HydrochlorideAngina pectorisCarteolol HydrochlorideArrhythmiaCarteolol HydrochlorideMycobacterium tuberculosis infectionRifampicinMycobacterium leprae infectionRifampicinPulmonary tuberculosisRifampicinMeningococcal meningitisRifampicinCOVID-19RifampicinRespiratory viral infectionRifampicin

Source drugs (routes using this intermediate)

DrugTierExpiry
RivaroxabanTier A — Act now2026
Atorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilTier C — Watch / trade-
Tadalafil/TamsulosinTier C — Watch / trade-
Carteolol Hydrochloride/LatanoprostTier C — Watch / trade-
Solifenacin Succinate/Tamsulosin HydrochlorideTier C — Watch / trade-
Dutasteride/Tamsulosin HydrochlorideTier C — Watch / trade-
Enalapril Maleate/Folic AcidTier C — Watch / trade-
Ethambutol Hydrochloride/Rifampicin/IsoniazidTier C — Watch / trade-
Brimonidine Tartrate/Timolol MaleateTier C — Watch / trade-
Bimatoprost/Timolol MaleateTier C — Watch / trade-
Tamsulosin HydrochlorideTier C — Watch / trade-
Enalapril MaleateTier C — Watch / trade-
Timolol MaleateTier C — Watch / trade-
Carteolol HydrochlorideTier C — Watch / trade-
RifampicinTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Ethambutol Hydrochloride/Rifampicin/IsoniazidOptimised routesteps: 4total yield: 14.02g(Rifampicin (FREE))
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→N,N-Dihydroxymethyl-t-butylamine→2-Methylpropan-2-amine→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-tert-Butyl-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-3,8,10,16,18,20,22,26-octamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-3-[2-(morpholin-4-yl)ethyl]-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-(1-Ethylpiperidin-3-yl)-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→4-Methylpiperazin-1-amine→N-Methylpiperazine
RifampicinOptimised routesteps: 4total yield: 14.02g(Rifampicin (FREE))
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→N,N-Dihydroxymethyl-t-butylamine→2-Methylpropan-2-amine→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-tert-Butyl-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-3,8,10,16,18,20,22,26-octamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-3-[2-(morpholin-4-yl)ethyl]-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-(1-Ethylpiperidin-3-yl)-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→4-Methylpiperazin-1-amine→N-Methylpiperazine

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Qualified Partner — East China API Works4-(4-Aminophenyl)morpholin -3-one
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Nantong cGMP Site(S)-(+)-N-(2,3-Epoxypropyl)phthalimide
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Taizhou GMP-like Site5-Chlorothiophene-2-carboxylic acid
Pharmaceutical Intermediates
On requestOn requestOn request
—
Qualified Partner — East China API Works5-Chlorothiophene-2-carbonyl chloride
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Nantong cGMP Site2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Taizhou GMP-like Site4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride
Pharmaceutical Intermediates
On requestOn requestOn request
—
Qualified Partner — East China API Works2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.